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Sex hormones and risk of breast cancer in premenopausal 
women: a collaborative reanalysis of individual participant 
data from seven prospective studies
Endogenous Hormones and Breast Cancer Collaborative Group*
Summary
Background Associations between circulating concentrations of oestrogens, progesterone, and androgens with breast 
cancer and related risk factors in premenopausal women are not well understood. We aimed to characterise these 
associations with a pooled analysis of data from seven studies.
Methods Individual participant data for prediagnostic sex hormone and sex hormone-binding globulin (SHBG) 
concentrations were contributed from seven prospective studies. We restricted analyses to women who were 
premenopausal and younger than 50 years at blood collection, and to women with breast cancer diagnosed before age 
50 years. We estimated odds ratios (ORs) with 95% CIs for breast cancer associated with hormone concentrations by 
conditional logistic regression in cases and controls matched for age, date of blood collection, and day of cycle, with 
stratiﬁ cation by study and further adjustment for cycle phase. We examined associations of hormones with risk 
factors for breast cancer in control women by comparing geometric mean hormone concentrations in categories of 
these risk factors, adjusted for study, age, phase of menstrual cycle, and body-mass index (BMI). All statistical tests 
were two-sided.
Findings We included data for up to 767 women with breast cancer and 1699 controls in the risk analyses. Breast cancer 
risk was associated with a doubling in concentrations of oestradiol (OR 1·19, 95% CI 1·06–1·35), calculated free 
oestradiol (1·17, 1·03–1·33), oestrone (1·27, 1·05–1·54), androstenedione (1·30, 1·10–1·55), dehydroepiandrosterone 
sulphate (1·17, 1·04–1·32), testosterone (1·18, 1·03–1·35), and calculated free testosterone (1·08, 0·97–1·21). 
Breast cancer risk was not associated with luteal phase progesterone (doubling in concentration OR 1·00, 95% CI 
0·92–1·09), and adjustment for other factors had little eﬀ ect on any of these ORs. Cross-sectional analyses in control 
women showed several associations of sex hormones with breast cancer risk factors.
Interpretation Circulating oestrogens and androgens are positively associated with the risk for breast cancer in 
premenopausal women.
Funding Cancer Research UK.
Introduction
Risk of breast cancer is aﬀ ected by several reproductive 
and hormonal factors and endogenous sex hormones are 
also thought to inﬂ uence risk.1 Suﬃ  cient data now exist 
from studies of hormones and breast cancer in 
postmenopausal women to show that risk is positively 
associated with circulating concentrations of oestrogens 
and androgens,2–4 but fewer data are available for 
premenopausal women and hormone measurements are 
complicated by the substantial variation in hormone 
concentrations across the menstrual cycle.
The Endogenous Hormones and Breast Cancer 
Collaborative Group was established to undertake pooled 
analyses of individual data from prospective studies to 
increase the precision of the estimated associations of 
endogenous hormones with the risk of breast cancer.2 We 
report here a collaborative analysis of data from seven 
studies. We describe the associations of circulating 
concentrations of sex hormones with breast cancer risk, 
including examination of consistency between studies, 
associations in subgroups, and the eﬀ ects of adjustment 
for other risk factors. We also describe cross-sectional 
analyses of the associations of circulating sex hormones 
and sex hormone-binding globulin (SHBG) with risk 
factors for breast cancer. Our aim was to improve 
understanding of the role of premenopausal sex 
hormones in breast cancer diagnosed before menopause, 
because hormonal changes after menopause will 
probably inﬂ uence the association of premenopausal 
hormone levels with the risk for postmenopausal breast 
cancer. We therefore restricted all analyses to women 
who were premenopausal and younger than 50 years at 
blood collection, and to case–control sets in which the 
case patient was diagnosed with breast cancer before age 
50 years.
Methods
Data collection
Published studies were eligible for the collaborative 
reanalysis if they included data for endogenous 
hormones and breast cancer risk from prospectively 
collected blood samples of premenopausal women. 
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We included the following studies, which were identiﬁ ed 
by computer-aided literature searches and through 
discussions with colleagues: CLUE I, Washington 
County, MD, USA;5,6 Columbia, MO, USA;7 the European 
Prospective Investigation into Cancer and Nutrition 
(EPIC), Europe;8 Guernsey, UK;9 Nurses’ Health Study II 
(NHS-II), USA;10–12 New York University Women’s Health 
Study (NYU WHS), USA;13 and the Study of Hormones 
and Diet in the Etiology of Breast Tumors (ORDET), 
Italy.14 Most women in these studies were of white 
European ethnic origin. Two additional studies in the 
Collaborative Group had prospective hormone data but 
were not included in the analyses reported here because 
data for day of menstrual cycle at blood collection were 
not available: the Melbourne Collaborative Cohort Study, 
Australia,15 and Radiation Eﬀ ects Research Foundation 
study phases 1 and 2, Japan.16,17 One ﬁ nal study18 was 
identiﬁ ed but the data could not be retrieved; this study 
included 17 patients with breast cancer and 67 matched 
controls in women who were premenopausal at blood 
collection.
Table 1 summarises the designs of included studies. 
Participants in NHS-II were volunteers who were nurses, 
and in the other cohorts the participants were volunteers 
living in areas near the recruitment centres. Details of 
the recruitment of participants, informed consent, ethics 
approvals, and deﬁ nitions of reproductive variables are 
reported in the original publications. The present 
analyses did not need further ethics approval. Most cases 
were of invasive breast cancer, but ﬁ ve of the studies 
(Columbia, EPIC, NHS-II, NYU WHS, and ORDET) also 
included some in-situ cases. Cases were individually 
matched to between two and four controls: all studies 
matched participants on age and date of blood sample (or 
follow-up time for EPIC), and on the day or phase of 
menstrual cycle at blood collection. Collaborators were 
asked to provide data for concentrations of the hormones 
oestradiol (total), oestrone, progesterone, androstene-
dione, dehydroepiandrosterone sulphate (DHEAS), 
testosterone, and SHBG, and data for reproductive, 
anthropometric, and lifestyle factors for each woman in 
their study, when available. Women who used hormonal 
contraceptives or other exogenous sex hormones at the 
time of blood collection were excluded, as were women 
missing information for date of birth, date at blood 
collection, day of menstrual cycle at blood collection, or 
date of diagnosis (cases).
The appendix contains brief details of the assays used, 
with further details in the original publications. Six 
studies measured hormone concentrations in serum 
whereas one (NHS-II) used heparin plasma; for 
convenience we refer to serum concentrations for the 
Recruitment 
population
Recruitment 
period
Fasting status Storage 
temperature
Matching criteria
Controls 
per case
Age at blood 
collection
Date of blood 
sample
Day of cycle Other matching criteria
CLUE I, USA5,6 Residents of Washington 
County, MD, USA
1974 Non-fasting –70°C 2 ±1 year ±14 days ±1 day Time of day, fasting 
status, ethnic group, 
freeze–thaw history of 
serum sample
Columbia, USA7 Residents of Columbia, 
MO, USA
1977–89 Non-fasting –70°C 2 ±2 years ±1 year ±2 days Time of day at blood 
collection
EPIC, Europe8 Volunteers in Denmark, 
France, Germany, Greece, 
Italy, Netherlands, Spain, 
Sweden, and UK
1992–98 Matched –196°C* 2 ±6 months No (incidence 
density 
sampling) 
Five phases Time of day at blood 
collection, fasting status, 
subcohort
Guernsey, UK9 Residents of the island of 
Guernsey, UK 
1977–90 Non-fasting –20°C 3 ±2 years ±1 year ±1 day ..
Nurses’ Health Study II phases 1 
(1999–2003 follow-up cycles) 
and 2 (2005–09 follow-up 
cycles), USA10–12
Registered nurses in the 
USA
1996–99 Matched –130°C 2 ±2 years ±2 months ±1 day for 
luteal blood 
sample†
Time of day, fasting 
status 
NYU WHS, USA13 Women attending a 
breast cancer screening 
centre in New York, NY, 
USA
1985–91 Non-fasting –80°C 2 ±6 months ±3 months 5 phases 
and day
Number of subsequent 
samples
ORDET, Italy14 Residents of Varese 
province, Italy
1987–92 12 h fast before 
collection; 
samples taken 
0730–0900 h
–80°C 4 ±5 years ±89 days All days 
20–24
Daylight saving period, 
recruitment centre
CLUE I=Washington County, MD Study “Give us a clue to cancer and heart disease”. EPIC=European Prospective Investigation into Cancer and Nutrition. NYU WHS=New York University Women’s Health Study. 
ORDET=Study of Hormones and Diet in the Etiology of Breast Tumors. *Most samples were stored in liquid nitrogen at –196°C, apart from in Denmark where they were stored in nitrogen vapour at –150°C. 
†Patients were asked to provide follicular sample at 3–5 days and luteal sample at 7–9 days before anticipated start of next cycle.
Table 1: Prospective cohort studies combined in the collaborative reanalysis
See Online for appendix
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pooled analyses. We calculated circulating concentrations 
of free oestradiol and free testosterone from the 
concentrations of oestradiol and testosterone and of 
SHBG according to the law of mass action, with albumin 
assumed to be constant (40 g/L).19,20
Statistical analysis
We grouped day of cycle at blood collection into six 
categories, according to the number of days until next 
period if available (backward dating), otherwise according 
to days since last period (forward dating). The six categories 
were as follows: early follicular (day ≥24 backwards or 
days 1–5 forwards), late follicular (19–23 backwards or 
6–10 forwards), mid-cycle (15–18 backwards or 11–14 for-
wards), early luteal (11–14 backwards or 15–18 forwards), 
mid luteal (5–10 backwards or 19–24 forwards), or late 
luteal (0–4 backwards or ≥25 forwards). For CLUE I and 
Columbia, day of cycle was assessed with forward dating 
Women* Oestradiol, 
pmol/L
Calculated 
free 
oestradiol, 
pmol/L
Oestrone, 
pmol/L
Luteal phase 
progesterone, 
nmol/L
Androstenedione, 
nmol/L
DHEAS, 
nmol/L
Testosterone, 
nmol/L
Calculated 
free 
testosterone, 
pmol/L
SHBG,
nmol/L
CLUE I, USA5,6
Cases 21 172 
(134–222)
2·03 
(1·55–2·64)
252 
(211–301)
5·32 
(1·73–16·3)
2·98
(2·31–3·85)
3903 
(2787–5465)
·· ·· 69·9 
(58·0–84·2)
Controls 42 168 
(137–206)
1·85 
(1·51–2·26)
239 
(207–275)
9·62 
(5·47–16·9)
2·88
(2·42–3·43)
3853 
(3023–4910)
·· ·· 74·3 
(65·3–84·4)
Columbia, USA7
Cases 13 239 
(165–347)
3·26 
(2·24–4·75)
·· ·· ·· ·· 1·00 
(0·79–1·28)
13·7 
(9·86–19·1)
48·2 
(34·3–67·7)
Controls 24 316 
(257–387)
4·05 
(3·34–4·92)
·· ·· ·· ·· 0·86 
(0·73–1·02)
10·7 
(9·10–12·7)
56·6 
(48·3–66·4)
EPIC, Europe8
Cases 206 318 
(285–355)
4·60 
(4·13–5·12)
384 
(354–416)
8·42 
(6·30–11·3)
5·59
(5·22–5·98)
3712 
(3469–3972)
1·70 
(1·60–1·81)
25·2 
(23·2–27·3)
43·5 
(40·6–46·6)
Controls 408 296 
(275–318)
4·25 
(3·94–4·60)
360 
(339–383)
12·3 
(9·84–15·4)
4·92
(4·68–5·18)
3341 
(3169–3522)
1·56 
(1·49–1·63)
23·3 
(21·8–24·8)
43·0 
(40·9–45·3)
Guernsey, UK9
Cases 32 323 
(253–412)
3·16 
(2·39–4·17)
·· 10·7 
(5·84–19·5)
·· 2253 
(1410–3599)
1·17 
(0·97–1·40)
13·2 
(11·3–15·5)
68·6 
(59·5–79·1)
Controls 94 282 
(246–323)
3·02 
(2·52–3·62)
·· 10·6 
(7·25–15·4)
·· 2548 
(1924–3375)
1·12 
(1·02–1·23)
13·4 
(11·6–15·5)
61·5 
(55·8–67·7)
Nurses’ Health Study II phase 1, USA10,11
Cases 139 182 
(166–199)
2·30 
(2·12–2·49)
150 
(142–159)
45·7 
(41·1–50·8)
3·91
(3·68–4·16)
2302 
(2129–2489)
0·92 
(0·87–0·99)
11·3 
(10·5–12·2)
57·9 
(53·8–62·3)
Controls 268 164 
(153–177)
2·08 
(1·95–2·22)
145 
(138–151)
43·5 
(39·9–47·4)
3·89
(3·72–4·06)
2208 
(2089–2333)
0·90 
(0·86–0·94)
10·9 
(10·3–11·5)
58·5 
(55·5–61·8)
Nurses’ Health Study II phase 2, USA12
Cases 105 193 
(175–213)
2·21 
(2·02–2·42)
161 
(150–173)
40·7 
(34·6–47·9)
·· 2838 
(2556–3151)
0·91 
(0·85–0·98)
9·6
(8·7–10·5)
70·6 
(65·3–76·3)
Controls 203 186 
(174–199)
2·25 
(2·11–2·40)
163 
(154–171)
38·1 
(33·9–42·9)
·· 2642 
(2449–2851)
0·91 
(0·87–0·96)
10·6 
(10·0–11·3)
62·4 
(59·0–66·0)
NYU WHS phase 2, USA13
Cases 137 ·· ·· ·· ·· 4·30
(3·96–4·67)
3978 
(3625–4366)
1·01 
(0·91–1·12)
14·0 
(12·4–15·8)
48·1 
(44·1–52·4)
Controls 258 ·· ·· ·· ·· 4·07
(3·83–4·33)
3869 
(3598–4161)
0·95 
(0·88–1·03)
13·1 
(11·9–14·3)
47·8 
(44·8–51·0)
ORDET, Italy14
Cases 84 300 
(274–329)
3·66 
(3·34–4·00)
·· 38·2 
(32·7–44·6)
5·26
(4·38–6·32)
3856 
(3153–4715)
0·85 
(0·75–0·97)
9·9 
(8·5–11·6)
62·0 
(56·6–68·0)
Controls 336 282 
(259–306)
3·50 
(3·23–3·79)
·· 32·4 
(28·3–37·1)
5·79
(5·38–6·23)
3921 
(3604–4265)
0·84 
(0·79–0·90)
10·1 
(9·3–10·8)
59·8 
(57·1–62·6)
Geometric mean hormone concentrations for Nurses’ Health Study II are obtained using the follicular phase data for oestradiol, calculated free oestradiol and oestrone and using the luteal phase data for all other 
hormones. DHEAS=dehydroepiandrosterone sulphate. SHBG=sex hormone-binding globulin. CLUE I=Washington County, MD Study “Give us a clue to cancer and heart disease”. EPIC=European Prospective 
Investigation into Cancer and Nutrition. NYU WHS=New York University Women’s Health Study. ORDET=Study of Hormones and Diet in the Etiology of Breast Tumors. ··=data not available. *Women with known 
phase of cycle and values for oestradiol (apart from NYU WHS, in which numbers are for women with values for testosterone).
Table 2: Geometric mean hormone concentrations (with 95% CIs) 
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for all participants. For Guernsey and NHS-II, day of cycle 
was determined backwards for all participants (apart from 
one case in NHS-II). For the other three studies, the 
percentages of patients determined with backward dating 
(otherwise forward dating) were as follows: 54·4% for 
cases and 51·0% for controls in EPIC; 75·2% for cases and 
82·9% for controls in NYU WHS; and 94·0% for cases 
and 96·1% for controls in ORDET.
In NHS-II, participants provided two blood samples at 
baseline, one collected in the follicular phase and one in 
the luteal phase. For most of the analyses reported here 
we use values for oestradiol and oestrone from the 
follicular phase, and progesterone, androstenedione, 
DHEAS, testosterone, and SHBG from the luteal phase; 
in the analyses of oestradiol and free oestradiol 
subdivided by phase of cycle we used both the follicular 
and the luteal measures, as appropriate. In the other 
studies, only one blood sample was collected from each 
participant.
All women were classiﬁ ed as premenopausal in the 
contributed datasets, with the criteria for this based on 
questionnaire information, as described in the original 
studies; three studies additionally measured serum 
follicle-stimulating hormone (FSH) concentration and 
excluded women with FSH values higher than the cutoﬀ  
recommended by their laboratory (Guernsey, NYU 
WHS, and ORDET). We restricted analyses to cases 
diagnosed before age 50 years (and their matched 
controls), so that most cases would have been diagnosed 
when premenopausal; this restriction further served to 
reduce the possibility that some participants were peri-
menopausal at blood collection.
All included studies used a nested case–control 
design, with assays arranged so that case–control sets 
were generally measured in the same batch, thus 
eliminating interassay variation from the case–control 
comparisons. We retained the original matched sets in 
the analyses. Some studies used density sampling, 
meaning that an individual participant could appear 
more than once in a data ﬁ le.
We used conditional logistic regression to estimate 
the odds ratio (OR) for breast cancer in relation to the 
serum concentrations of hormones and SHBG, 
categorising women in each study according to the 
quintiles of hormone concentration for the controls in 
that study, after standardisation for phase of menstrual 
cycle with residuals from the study-speciﬁ c mean for 
each cycle phase; for progesterone, we restricted the 
analysis to samples collected in the luteal phase. For 
each study, we ﬁ tted the simple linear regression model: 
log(hormone) = A + B × (phase of cycle), where phase of 
cycle was a categorical variable. The residuals from this 
model were then added to the mean log(hormone) value 
and the result exponentiated to give the standardised 
value. We used study-speciﬁ c quintile cut-points 
because the absolute concentrations of hormones and 
SHBG vary between studies due to laboratory variation; 
further explanation of this approach is provided in 
previous publications.2,21 To test for the signiﬁ cance of 
the association and to provide a summary measure of 
risk we also estimated the OR associated with a unit 
increase in a continuous variable equal to the logarithm 
to the base 2 of the hormone concentration. A unit 
increase in this variable is equivalent to a doubling in 
hormone concentration. Heterogeneity in linear trends 
between studies was tested by comparing the χ² values 
for models with and without a (study) × (linear trend) 
interaction term. We also used χ² tests to examine 
whether evidence of heterogeneity existed in the 
associations of hormones with risk of breast cancer 
according to subgroups deﬁ ned according to years from 
blood collection to diagnosis (<4 years or ≥4 years), stage 
Figure 1: Geometric mean oestradiol concentrations (A) and progesterone 
concentrations (B), by phase of menstrual cycle
Adjusted for study and age at blood collection. Vertical lines show 95% CIs.
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of disease (in situ or invasive), oestrogen receptor status 
(positive or negative), progesterone receptor status 
(positive or negative), HER2 receptor status (positive or 
negative), phase of menstrual cycle at blood collection 
(apart from for progesterone; follicular, mid-cycle, or 
luteal), age at menarche (<14 years or ≥14 years), parity 
(nulliparous or parous), age at ﬁ rst full-term pregnancy 
(<25 years or ≥25 years), mother or sister with breast 
cancer (no or yes), body-mass index (BMI; <25 kg/m² or 
≥25 kg/m²), smoking (never or past, current), alcohol 
intake at recruitment (<10 g per day or ≥10 g per day), 
previous use of hormonal contraceptives (no or yes), 
and assay method for oestradiol, calculated free 
oestradiol, oestrone, testosterone, and calculated free 
testosterone (extraction or non-extraction). We also 
investigated the associations of hormones with breast 
cancer risk after adjustment for reproductive and 
hormonal risk factors for breast cancer: age at menarche 
(<12 years, 12–13 years, ≥14 years, or unknown); parity 
(zero, one, two, three, or four or more full-term 
pregnancies, or unknown); age at ﬁ rst full-term 
pregnancy (<20 years, 20–24 years, 25–29 years, 
≥30 years, or unknown); BMI (<22·5 kg/m², 
22·5–24·9 kg/m², 25·0–27·4 kg/m², 27·5–29·9 kg/m², 
≥30·0 kg/m², or unknown).
Concentrations of the hormones and SHBG were 
positively skewed, we therefore used log-transformed 
concentrations for all parametric analyses. We examined 
associations of hormones with risk factors for breast 
cancer in the controls; the numbers of controls in these 
analyses were somewhat larger than the numbers in the 
risk analyses because all controls who were pre-
menopausal and aged younger than 50 years at blood 
collection were eligible, irrespective of the age at blood 
collection or diagnosis of their matched case. We 
calculated geometric means and 95% CIs according to 
categories of these factors, adjusting for study, age 
(<40 years, 40–44 years, and 45–49 years), cycle phase, 
and BMI, as appropriate. We used F tests to assess 
heterogeneity in the geometric mean hormone 
concentrations between the categories of risk factors, 
and where appropriate to test for trends across the 
categories, with the ordered categories scored from 1 to 
the maximum number of categories. The heterogeneity 
between studies in the associations of hormones with 
risk factors was assessed by adding a (study) × (factor) 
interaction term to the model and using the F test to 
calculate its signiﬁ cance.
Figure 2: Odds ratios for breast cancer associated with sex hormones and SHBG
Black squares show odds ratios in quintiles (Q1–Q5; study-speciﬁ c ﬁ fths after 
adjustment for phase of cycle within each study), and the horizontal lines show 
95% CIs. The area of each square is proportional to the amount of statistical 
information (inverse of the variance of the logarithm of the odds ratios). The 
diamonds show the odds ratio for a doubling in concentration, and the widths of 
the diamonds show the 95% CIs. Estimates are from conditional logistic 
regression on case–control sets matched within each study. 
DHEAS=dehydroepiandrosterone sulphate. SHBG=sex hormone-binding globulin.
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1·28 (0·96–1·70)
1·07 (0·94–1·23)
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All statistical tests were two-sided and we set statistical 
signiﬁ cance at the 5% level. All analyses were done with 
Stata version 12.0.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The members of the writing 
committee had full access to all data in the study and had 
the ﬁ nal responsibility for the decision to submit the 
manuscript for publication.
Results
We included 767 women with breast cancer and 
1699 matched controls from the seven studies in the 
risk analyses; all these women had data on SHBG, with 
smaller numbers for the individual sex hormones. 
Mean age at blood collection ranged from 35·6 years for 
cases in CLUE to 42·2 years for cases and controls in 
EPIC (appendix p 4). The median time between blood 
collection and diagnosis ranged from 2 years in EPIC to 
9 years in CLUE. Geometric mean concentrations of sex 
hormones and SHBG in controls ranged from 
164 pmol/L to 316 pmol/L for oestradiol, 1·85 pmol/L to 
4·25 pmol/L for calculated free oestradiol, 145 pmol/L 
to 360 pmol/L for oestrone, 9·62 nmol/L to 43·5 nmol/L 
for luteal phase progesterone, 2·88 nmol/L to 
5·79 nmol/L for androstenedione, 2208 nmol/L to 
3921 nmol/L for DHEAS, 0·84 nmol/L to 1·56 nmol/L 
for testosterone, 10·1 pmol/L to 23·3 pmol/L for 
calculated free testosterone, and 43·0 nmol/L to 
74·3 nmol/L for SHBG (table 2).
Figure 1 shows geometric mean concentrations of 
oestradiol and progesterone in cases and controls by 
phase of menstrual cycle at blood collection. For 
oestradiol, geometric mean values were higher, although 
not statistically signiﬁ cantly so in cases than in controls 
at cycle phases apart from the late luteal phase. For 
progesterone, geometric means were lower in cases than 
controls in the early luteal phase, with small non-
signiﬁ cant diﬀ erences in the other phases.
Concentrations of oestradiol, calculated free oestradiol, 
oestrone, androstenedione, DHEAS, and testosterone 
were positively associated with breast cancer risk 
(ﬁ gure 2). Concentrations of luteal phase progesterone, 
calculated free testosterone, and SHBG were not 
signiﬁ cantly associated with such risk. In a sensitivity 
analysis restricted to women with blood collected at ages 
younger than 45 years and breast cancer diagnosed 
before age 45 years the results showed similar trends 
(appendix p 5). We noted no signiﬁ cant heterogeneity 
between studies in the associations of these hormones 
with breast cancer risk (appendix pp 6–14). Further 
adjustment for age at menarche, age at ﬁ rst full-term 
pregnancy, number of full-term pregnancies, and BMI 
did not substantially change the ORs, apart from that 
after adjustment we noted a signiﬁ cant positive 
association of calculated free testosterone with risk (OR 
for a doubling was 1·14, 95% CI 1·01–1·28; ptrend=0·031; 
appendix p 15).
Appendix pp 16–24 show results of the subgroup 
analyses. Four of 130 tests for heterogeneity were 
signiﬁ cant in our subgroup analyses of the nine hormones: 
for oestradiol the OR for a doubling in concentration was 
1·26 (95% CI 1·10–1·44) for never or past smokers and 
0·94 (0·75–1·18) for current smokers (pheterogeneity=0·034); 
1·01 (0·82–1·24) for never users and 1·32 (1·14–1·53) for 
past users of hormonal contraceptives (pheterogeneity=0·030); 
for oestrone the OR for a doubling in concentration was 
1·74 (0·99–3·03) for progesterone receptor-positive 
cancers and 0·54 (0·27–1·08) for progesterone receptor-
negative cancers (pheterogeneity=0·010); and for luteal phase 
progesterone the OR for a doubling in concentration was 
1·25 (1·01–1·55) for nulliparous women and 0·99 
(0·90–1·09) for parous women (pheterogeneity=0·034).
Three subgroup analyses were of particular a-priori 
interest. No evidence suggested that any of the ORs 
varied by the time between blood collection and diagnosis 
(appendix pp 16–24). For oestrogens and androgens, the 
ORs were larger for oestrogen-receptor positive tumours, 
the ORs were larger for oestrogen receptor-positive 
tumours than they were for oestrogen receptor-negative 
tumours, but none of these diﬀ erences were signiﬁ cant 
(table 3). For oestradiol according to phase of menstrual 
cycle the ORs for a doubling in concentration were 1·25 
(95% CI 1·06–1·48) for follicular samples, 1·20 
(0·81–1·79) for mid-cycle samples, and 1·13 (0·92–1·37) 
for luteal samples (pheterogeneity=0·732; appendix p 16).
Compared with women with a BMI of less than 
22·5 kg/m², women with a BMI of 30 kg/m² or more had 
lower mean concentrations of oestradiol (by 17%), luteal 
phase progesterone (by 28%), and SHBG (by 46%); 
conversely, we noted a positive association with BMI for 
mean concentrations of calculated free oestradiol (by 
 Oestrogen receptor positive Oestrogen receptor negative pheterogeneity
Cases/
controls
Odds ratio 
(95% CI)
Cases/
controls
Odds ratio 
(95% CI)
Oestradiol 147/374 1·25 (0·95–1·65) 71/209 1·09 (0·76–1·57) 0·56
Calculated free oestradiol 147/374 1·22 (0·91–1·63) 71/209 1·03 (0·68–1·54) 0·50
Oestrone 107/205 1·26 (0·77–2·06) 37/72 0·90 (0·45–1·82) 0·45
Luteal phase progesterone 152/369 1·05 (0·88–1·24) 67/184 1·13 (0·88–1·47) 0·62
Androstenedione 124/237 1·45 (0·98–2·15) 54/106 1·11 (0·58–2·14) 0·50
DHEAS 170/327 1·24 (0·97–1·57) 67/130 0·91 (0·62–1·34) 0·19
Testosterone 211/495 1·13 (0·88–1·43) 99/265 1·03 (0·76–1·39) 0·66
Calculated free testosterone 211/495 1·08 (0·88–1·33) 99/264 1·01 (0·78–1·30) 0·66
SHBG 214/503 1·04 (0·80–1·35) 102/271 1·08 (0·77–1·52) 0·86
Estimates are from conditional logistic regression on case–control sets matched within each study and adjusted for 
phase of menstrual cycle at blood collection within study. DHEAS=dehydroepiandrosterone sulphate. SHBG=sex 
hormone-binding globulin.
Table 3: Odds ratios for breast cancer associated with a doubling in concentrations of hormones and 
SHBG, subdivided by oestrogen receptor status
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10%), oestrone (by 16%), DHEAS (by 8%), testosterone 
(by 7%), and calculated free testosterone (by 63%), with 
means adjusted for age, study, and cycle phase (ﬁ gure 3).
Appendix pp 25–31 show the associations of sex 
hormones with age at blood collection, age at menarche, 
parity, family history of breast cancer, smoking, alcohol 
intake at recruitment, and previous use of hormonal 
contraceptives. Concentrations of sex hormones were 
lower in older women than in younger women, whereas 
SHBG was higher in older women (appendix p 25). Parity 
was inversely associated with calculated free testosterone, 
but was not associated with concentrations of the other 
sex hormones or SHBG (appendix p 27), and none of the 
hormones or SHBG was associated with age at menarche 
or family history of breast cancer (appendix pp 26, 28). 
Compared with never-smokers, current smokers of at 
least 15 cigarettes per day had increased concentrations of 
androstenedione (by 21%), DHEAS (by 12%), testosterone 
(by 12%), and calculated free testosterone (by 13%; 
appendix p 29). Compared with women who did not 
consume alcohol, women with an alcohol intake of at 
least 20 g per day had increased concentrations of 
androstenedione (by 13%), DHEAS (by 16%), testosterone 
(by 23%), and calculated free testosterone (by 23%; 
appendix p 30). Further adjustment of the analyses by 
smoking for alcohol, and of the analyses by alcohol for 
smoking, had no material eﬀ ect on the results (data not 
shown). Women who had previously used hormonal 
contraceptives had lower concentrations of oestradiol 
(by 7%), oestrone (by 7%), androstenedione (by 5%), and 
SHBG (by 4%) than did women who had not used 
hormonal contraceptives (appendix p 31).
Discussion
Our worldwide collaboration brought together and 
reanalysed individual participant data from seven studies 
of risk of breast cancer and endogenous sex hormones 
measured in prospectively collected blood samples (panel). 
All women were premenopausal and provided information 
about the phase of the menstrual cycle at the time of blood 
collection. Oestradiol, calculated free oestradiol, oestrone, 
androstenedione, DHEAS, and testosterone concentrations 
were positively associated with risk of breast cancer, 
whereas luteal phase progesterone and SHBG were not 
associated with risk. Calculated free testosterone was 
positively associated with breast cancer risk only after 
adjustment for reproductive factors and BMI. These 
associations did not vary according to the time between 
blood collection and diagnosis, making reverse causality 
unlikely, and (with the exception of calculated free 
Figure 3: Geometric mean hormone and SHBG concentrations (with 95% CIs) 
in controls, by body-mass index
Adjusted for study, age at blood collection, and phase of menstrual cycle. 
*Means scaled to overall mean concentration (vertical line). †Signiﬁ cant 
(p<0·05) interaction with study. DHEAS=dehydroepiandrosterone sulphate. 
SHBG=sex hormone-binding globulin.
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testosterone) were not materially aﬀ ected by adjustment 
for other risk factors, suggesting that confounding is 
unlikely. These results therefore strongly suggest that 
breast cancer risk in premenopausal women increases 
with increasing concentrations of these sex hormones. 
The results are qualitatively similar to those reported in 
postmenopausal women, but smaller in magnitude.2–4
The analyses reported in this paper were all based on a 
one-oﬀ  hormone measurement for each woman. 
Measurements of hormone concentrations are subject to 
random error associated with assay variation, and 
ﬂ uctuations in serum levels within individual women. 
Studies of the reproducibility of sex hormones in 
premenopausal women for up to 3 years have shown 
intraclass correlations of about 0·6 or above for 
androgens and SHBG, but correlations of about 0·4 or 
less for oestrogens and progesterone.22,23 Therefore our 
reported associations between hormone concentrations 
and breast cancer risk are probably underestimates of the 
true associations, particularly for oestrogens, but more 
reproducibility data are required.
Our subgroup analyses showed heterogeneity in the 
associations of oestradiol with risk according to smoking 
and previous use of hormonal contraceptives, of oestrone 
with risk according to progesterone receptor status, and 
of luteal phase progesterone with risk according to parity, 
but there was no signiﬁ cant heterogeneity according to 
any other combination of risk factors and hormones. All 
the sex hormones had larger associations with the risk of 
oestrogen receptor-positive breast cancer than they did 
with the risk of oestrogen receptor-negative disease; 
these diﬀ erences were not statistically signiﬁ cant, but 
study power was low because of the small numbers of 
cases with oestrogen receptor-negative disease (eg, 
71 cases for oestradiol). Because we did 130 subgroup 
analyses, some of the four analyses that were nominally 
signiﬁ cant may have occurred from chance.
For oestradiol, the plot of geometric mean con-
centrations in cases and controls according to phase of 
menstrual cycle (ﬁ gure 1) suggested that concentrations 
in cases were higher than those in controls in the 
follicular phase and at mid-cycle, but not in the late luteal 
phase, and similarly the subgroup analyses of breast 
cancer risk showed larger ORs in the follicular phase and 
at mid-cycle than in the luteal phase, but these diﬀ erences 
were not statistically signiﬁ cant.
Concentrations of all nine hormones, apart from 
androstenedione, were associated with BMI. Total 
oestradiol was inversely associated with BMI, whereas 
free oestradiol was positively associated with BMI 
because of the strong inverse association of SHBG with 
BMI. Interpretation of these observations is diﬃ  cult, but 
if free oestradiol is a reliable index of bioavailable 
oestradiol then obese premenopausal women are 
exposed to a slightly more oestrogenic environment. 
Oestrone was also positively associated with BMI, 
perhaps because of increased peripheral aromatisation of 
androstenedione, as in postmenopausal women.24 Pro-
gesterone concentrations were lower in obese than in 
non-obese women, whereas DHEAS and testosterone 
were positively associated with BMI. Similar ﬁ ndings for 
oestrogens and progesterone have been reported among 
regularly menstruating women in the BioCycle Study,25 
and in massively obese premenopausal women.26
Parity was not strongly associated with any of the 
hormones, but showed an inverse association with 
calculated free testosterone. Some previous studies in 
younger premenopausal women have suggested that 
early menarche and nulliparity are associated with 
oestrogen levels,27,28 but in the current study none of the 
hormones or SHBG were signiﬁ cantly associated with 
age at menarche, and none of the oestrogen measures 
was associated with parity.
Concentrations of androstenedione, DHEAS, testos-
terone, and free testosterone were higher in women who 
smoked the most cigarettes and drank the most alcohol 
than they were in respective groups of non-smokers and 
non-drinkers. Very similar associations were noted in 
postmenopausal women.29 The mechanism might involve 
stimulation of hormone synthesis by the adrenal glands.30
Women who had previously used hormonal 
contraceptives had lower concentrations of oestradiol, 
oestrone, androstenedione, and SHBG. Whether these 
associations are causal is unclear, as is what mechanism 
could be involved, although it might involve long-term 
eﬀ ects on the liver.31
Panel: Research in context
Systematic review
Literature on epidemiological studies of breast cancer was 
identiﬁ ed from electronic searches of PubMed between Jan 1, 
1980, and June 30, 2012, with combinations of the search 
terms “breast cancer” and “endogenous hormones”, 
supplemented by searching review articles, and discussions 
with colleagues. Eligible studies needed to have sex hormone 
concentrations measured in serum or plasma collected 
prospectively from women who subsequently developed 
breast cancer and from control women who did not develop 
breast cancer. In addition, studies needed to have information 
on the stage of the menstrual cycle at blood collection.
Interpretation
We included seven eligible studies and principal investigators 
contributed information from 767 women with breast 
cancer. We report on the relation of circulating 
concentrations of eight sex hormones and sex hormone-
binding globulin (SHBG) with breast cancer risk, overall and 
by subgroups, including stage of disease, receptor status of 
tumours, and other risk factors for breast cancer. We also 
describe the associations of sex hormones with risk factors 
for breast cancer in the control women. Breast cancer risk was 
positively associated with circulating concentrations of 
oestrogens and androgens.
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Sex hormones might mediate the eﬀ ects of some risk 
factors on the development of breast cancer. For example, 
the increase in risk of breast cancer caused by alcohol32 
might be attributable to increased serum concentrations 
of sex hormones, although it could also be attributable to 
other eﬀ ects of alcohol. BMI is inversely associated with 
the risk of breast cancer in premenopausal women,33 and 
this association might be related to the eﬀ ects of obesity 
on hormone levels. We noted that total oestradiol was 
inversely related to BMI and positively associated with 
risk, which is compatible with the idea that the lower risk 
in obese women is attributable to lower oestradiol, but 
this interpretation is complicated by the fact that we 
noted that free oestradiol was positively associated with 
BMI, as were oestrone and the androgens DHEAS, 
testosterone, and free testosterone. Luteal phase 
progesterone was also lower in obese than normal weight 
women, perhaps because of a higher probability of 
anovulatory cycles in obese women;34 our analyses do not 
show any association of progesterone with risk of breast 
cancer, but the reliability of progesterone measurements 
is low and more data are needed before conclusions can 
be made that progesterone is not a determinant of breast 
cancer risk.
The strengths of this analysis were that the data and 
serum samples were collected on average several years 
before diagnosis, that we included almost all the available 
data from published studies worldwide, and we were able 
to adjust for phase of cycle and for other potential risk 
factors. The total sample size was moderately large for 
most of the hormones, but the power was low for the 
subgroup analyses. Many statistical tests are reported, 
therefore some of the nominally signiﬁ cant results may 
be due to chance.
A potential limitation was that the study designs and 
methods for measurement of hormones and other risk 
factors were not standardised. For example, studies 
variably used forward or backward dating for 
determination of when blood was collected in the 
menstrual cycle, and, because of diﬀ erences in 
progesterone measurement between studies, we were 
unable to distinguish ovulatory versus anovulatory cycles. 
Furthermore, hormone concentrations varied sub-
stantially between studies. Some of this variation in 
mean hormone concentrations between studies was due 
to diﬀ erences in the timing of sample collection, for 
example the relatively low mean oestradiol concentrations 
in the follicular phase in NHS-II samples that were 
collected on days 3–5 of the cycle, and the relatively high 
mean luteal phase progesterone concentrations in 
NHS-II and ORDET samples that were collected in the 
middle of the luteal phase. Some of the variation between 
studies probably shows diﬀ erences in assay methods. 
The accuracy of assay methods varies, and assays that 
incorporate an extraction step are more accurate than are 
direct non-extraction assays.35 Ideally, assays would be 
standardised and use the most accurate methods 
available, but in the present analysis our aim was to 
make the best use of the data available. To allow for 
diﬀ erences in absolute hormone concentrations between 
assay laboratories we used study-speciﬁ c quintiles of 
hormone con centrations.21 This approach assumes that 
the true concentrations across the quintiles are similar in 
all the studies, and if this assumption is not correct then 
the estimates of ORs might be biased. However, because 
heterogeneity in risk estimates was not evident between 
studies or between assay methods (extraction vs non-
extraction) this assumption does seem reasonable. 
Random error in laboratory estimates would lead to 
some underestimation of the associations observed.
Another potential limitation was that we used diagnosis 
of breast cancer before age 50 years as a surrogate for 
diagnosis before menopause. The median age at 
menopause in high-income countries is typically older 
than 50 years;36 therefore, with the cutoﬀ  of 50 years most 
women would have been premenopausal at the time of 
breast cancer diagnosis, and the few women who were 
postmenopausal at diagnosis would on average have had 
menopause recently. Furthermore, most women in these 
studies were of white European ethnic origin, and further 
data for women with other ethnic origins would be 
valuable.
This collaborative analysis noted a positive association 
between sex hormones and breast cancer risk in 
premenopausal women. Whether or not this association 
is causal is not known, but plausible biological 
mechanisms exist that could explain such an eﬀ ect, 
such as an increase in the mitotic rate of breast epithelial 
cells leading to an increased risk of mutations and the 
stimulation of the growth of early tumours.37 
The magnitude of the reported association was modest, 
but the true association could be substantially larger 
because of measurement error in the assessment of 
long-term premenopausal hormone levels. More data 
will become available in the next few years, both from 
extended follow-up of some of the studies in the present 
collaborative analysis, and from some new large studies 
such as the Breakthrough Generations Study38 and UK 
Biobank.39 More robust estimates are needed of the 
overall associations and associations in subgroups, as 
well as further analyses to clarify the relative importance 
of the diﬀ erent sex hormones, and to determine the 
environmental and genetic factors that cause diﬀ erences 
in hormone levels in premenopausal women.
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